Palisade Bio, Inc.(PALI)

$2.06—

Chart

Palisade Bio, Inc.(PALI)

NASDAQ

$2.06—

Chart Studio

PALI(PALI)

PALI

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.06

Nov 9, 2026

Revenue Estimate

$465,302

Analyst Sentiment

Wall St. Consensus

Buy

3 analysts·Low coverage

Score

3 Buy (100%)0 Hold (0%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

3100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$2.00

-2.9%

Consensus

$4.50

+118.4%

Bull

$7.00

+239.8%

12-Month Target Range3 analysts

$2.00$4.50$7.00

Current $2.06Consensus

Current Price

$2.06

Upside to Consensus

$2.44

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+11032.81%

EPS—

FY2028

Rev+69.83%

EPS—

FY2029

Rev+156.27%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$428,571	$48M	$81M	$208M	$374M
Low	$428,571	$48M	$81M	$208M	$374M
High	$428,571	$48M	$81M	$208M	$374M
EBITDA Avg	$257,142	$29M	$49M	$125M	$224M
Low	$257,142	$29M	$49M	$125M	$224M
High	$257,142	$29M	$49M	$125M	$224M
EBIT Avg	$257,142	$29M	$49M	$125M	$224M
Low	$257,142	$29M	$49M	$125M	$224M
High	$257,142	$29M	$49M	$125M	$224M
Net Income Avg	$-12M	$-17M	$-20M	$-21M	$-5M
Low	$-14M	$-22M	$-26M	$-21M	$-5M
High	$-11M	$-11M	$-15M	$-21M	$-5M
EPS Avg	$-0.23	$-0.28	$-0.33	$-0.37	$-0.09
Low	$-0.25	$-0.40	$-0.46	$-0.37	$-0.09
High	$-0.20	$-0.20	$-0.27	$-0.37	$-0.09
Analysts (Rev / EPS)	5 / 7	7 / 7	6 / 6	4 / 3	3 / 2

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$465,302	$433,012	$402,963	$375,000	$348,976	$324,759
Low	$465,302	$433,012	$402,963	$375,000	$348,976	$324,759
High	$465,302	$433,012	$402,963	$375,000	$348,976	$324,759
EBITDA Avg	$279,181	$259,807	$241,777	$225,000	$209,385	$194,855
Low	$279,181	$259,807	$241,777	$225,000	$209,385	$194,855
High	$279,181	$259,807	$241,777	$225,000	$209,385	$194,855
EBIT Avg	$279,181	$259,807	$241,777	$225,000	$209,385	$194,855
Low	$279,181	$259,807	$241,777	$225,000	$209,385	$194,855
High	$279,181	$259,807	$241,777	$225,000	$209,385	$194,855
Net Income Avg	$-13M	$-14M	$-14M	$-14M	$-16M	$-16M
Low	$-15M	$-19M	$-14M	$-14M	$-16M	$-16M
High	$-11M	$-12M	$-14M	$-14M	$-16M	$-16M
EPS Avg	$-0.06	$-0.07	$-0.07	$-0.07	$-0.07	$-0.07
Low	$-0.07	$-0.09	$-0.07	$-0.07	$-0.07	$-0.07
High	$-0.05	$-0.06	$-0.07	$-0.07	$-0.07	$-0.07
Analysts (Rev / EPS)	1 / 6	1 / 6	1 / 2	1 / 2	1 / 2	1 / 2

Earnings Surprises

Recent Analyst Actions

Jun 30, 2026Oppenheimer

H.C. Wainwright Reiterates Buy Rating on Palisade Bio Inc. (PALI)

Target:$7.00

+213.9%from $2.23

Jun 30, 2026H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Palisade Bio Inc. (PALI)

Target:$2.00

-10.3%from $2.23

Nov 17, 2023Maxim Group

Maxim Group Upgrades Palisade Bio Inc. (PALI) to Buy

Target:$1.50

-83.5%from $9.07

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance